Caplin Point Laboratories announced today that the company has received approval from Brazil's National Health Surveillance Agency, ANVISA (Agencia Nacional de Vigilancia Sanitaria) for its sterile injectable manufacturing site at Chennai.

The approval grants access to the company to register and market its products at the large and growing Brazilian pharmaceutical market.

The facility is capable of manufacturing liquid injectables in vials, ampoules, lyophilized vials and ophthalmic dosages, was also recently approved by European Union good manufacturing practice (EU-GMP) in July.

Shares of the company gained Rs 142, or 10.19%, to trade at Rs 1,535.00. The total volume of shares traded was 35,812 at the BSE (1.57 p.m., Thursday).